Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.71 |
| ▸ | ESRRG | P62508 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19786407 | 1.00 | ESR1 (0.73) | ESR1CYP19A1ESR2ESRRGHTR1D | |
| SCHEMBL26173595 | 1.00 | ESR1 (0.73) | ESR1CYP19A1ESR2ESRRGHTR1D | |
| SCHEMBL26775740 | 0.94 | ESR1 (0.64) | ESR1CYP19A1ESR2ESRRGHTR1D | |
| SCHEMBL10828013 | 0.87 | ESR1 (0.68) | ESR1CYP19A1ESR2DRD2DRD4 | |
| SCHEMBL10827624 | 0.87 | ESR1 (0.68) | ESR1CYP19A1ESR2DRD2DRD4 | |
| Endoxifen SCHEMBL10107920 | 0.84 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| SCHEMBL30578631 | 0.84 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| SCHEMBL15669002 | 0.84 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| Endoxifen SCHEMBL8655920 | 0.84 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| SCHEMBL30534784 | 0.84 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680036-B1 | Methods for making and using endoxifen | ATOSSA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230183166-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ATOSSA THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-11572334-B2 | Methods for making and using endoxifen | ATOSSA THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220175702-A1 | SUSTAINED RELEASE COMPOSITIONS OF ENDOXIFEN | ELEMENT MATERIALS TECHNOLOGY ANN ARBOR LLC | 2022-06-09 | — | — | US | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200268690-A1 | TOPICAL COMPOSITIONS | ATOSSA THERAPEUTICS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200215006-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | ATOSSA THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200207704-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ATOSSA THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2019051368-A1 | TOPICAL COMPOSITIONS | Atossa Genetics Inc. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20160346230-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346230-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | ESR1 17/4885CYP19A1 32/4885ESR2 23/4885 |
| US-20230183166-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ESR1, CYP19A1, ESR2 | ESR1 1/4885CYP19A1 2/4885ESR2 3/4885 |
| US-20200215006-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | CYP19A1, ESR1, SHBG | ESR1 2/4885CYP19A1 1/4885ESR2 6/4885 |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | ENPP2, ERAL1, LITAF | ESR1 18/4885CYP19A1 39/4885ESR2 4/4885 |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | EEF2K, LITAF, RAPGEF3 | ESR1 127/4885CYP19A1 2136/4885ESR2 25/4885 |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | ESR1 2480/4885CYP19A1 3591/4885ESR2 1235/4885 |
| US-11680036-B1 | Methods for making and using endoxifen | ESR1, CYP19A1, ESR2 | ESR1 1/4885CYP19A1 2/4885ESR2 3/4885 |
| US-11572334-B2 | Methods for making and using endoxifen | ESR1, CYP19A1, ESR2 | ESR1 1/4885CYP19A1 2/4885ESR2 3/4885 |
| US-20220175702-A1 | SUSTAINED RELEASE COMPOSITIONS OF ENDOXIFEN | CRH, CRHR2, ESR1 | ESR1 3/4885CYP19A1 39/4885ESR2 5/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | ESR1 127/4885CYP19A1 2136/4885ESR2 25/4885 |
| US-20200207704-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | SHBG, ESR1, ESR2 | ESR1 2/4885CYP19A1 4/4885ESR2 3/4885 |
| US-20200268690-A1 | TOPICAL COMPOSITIONS | CYP19A1, HSD17B11, CYP17A1 | ESR1 11/4885CYP19A1 1/4885ESR2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.